ARCHIVES

Imbruvica Improves PFS, OS In Phase III CLL Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

April 17, 1987

NCAB Gives President Evidence Supporting Limits On Tar, Nicotine

November 29, 1974

In Brief: Scientist Bands Entertain Writers

December 19, 1997

Griesmer To Leave NTP, Will Return To Oak Ridge

March 28, 1980

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

February 22, 2013

Step By Step: New Tenure Track, Appointments Process

August 5, 1994